Nabla vs Labcorp
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI clinical copilot. 85K+ clinicians, 130+ organizations. 20M patient interactions/year. Raised $70M Series C. Evolving to Adaptive Agentic Platform. Founded in Paris.
About
Nabla is a Paris-based clinical AI company founded in 2018 with a mission to reduce the documentation burden that is one of the primary drivers of clinician burnout across health systems globally. The company developed an AI clinical copilot that listens to patient-physician conversations and automatically generates structured clinical notes in the background, allowing clinicians to focus entirely on the patient rather than on documentation. Nabla's core technology applies large language models fine-tuned on medical language and SOAP note structure to produce accurate, editable documentation in real time.\n\nNabla's platform serves more than 85,000 clinicians across 130-plus organizations spanning hospitals, ambulatory practices, and digital health providers. It has facilitated over 20 million patient interactions per year, making it one of the highest-volume ambient AI documentation platforms in the market. The product supports more than 45 medical specialties, with specialty-specific note templates that reflect the distinct documentation requirements of fields ranging from psychiatry to orthopedics. Nabla is evolving its platform toward an Adaptive Agentic architecture, enabling the AI to take actions beyond note-taking — such as ordering follow-ups, drafting referrals, and surfacing clinical decision support.\n\nNabla raised a $70 million Series C to fund US expansion and platform development, following strong adoption in the European market. The company competes in the ambient clinical documentation space alongside Nuance DAX, Suki, and Abridge, but differentiates through its European regulatory expertise, multi-specialty coverage, and its strategic shift toward a full agentic clinical platform. With 20 million annual patient interactions and a clear product roadmap toward autonomous clinical workflow automation, Nabla is well positioned to grow into a broader clinical AI infrastructure role.
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
About
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.